Unknown PHASE1 INTERVENTIONAL 2-arm NCT03947879

The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II

Sponsor: Hawaii Pacific Health

Interventions L-glutamine No L-glutamine

Updated 5 times since 2019 Last updated: May 10, 2019 Started: May 31, 2019 Primary completion: May 31, 2021 Completion: May 31, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03947879, this PHASE1 trial focuses on Diabetes Mellitus, Type 2 and remains ongoing. Sponsored by Hawaii Pacific Health, it has been updated 5 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jun 2022 — Jul 2024 [monthly]

Unknown Status PHASE1

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Jun 2022 [monthly]

Not Yet Recruiting PHASE1
Jun 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1

First recorded

May 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hawaii Pacific Health

Data source: Hawaii Pacific Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.